Complete financial analysis of 23andMe Holding Co. (ME) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of 23andMe Holding Co., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Hard Off Corporation Co.,Ltd. (2674.T) Income Statement Analysis – Financial Results
- Unlimited Travel Group UTG AB (publ) (UTG.ST) Income Statement Analysis – Financial Results
- ANBANG SAVE-GUARD GROUP CO., LTD (603373.SS) Income Statement Analysis – Financial Results
- Fine besteel. Co., Ltd. (133820.KS) Income Statement Analysis – Financial Results
- SIZEMASTERS TECHNOLOGY LIMITED (SIZEMASTER.BO) Income Statement Analysis – Financial Results
23andMe Holding Co. (ME)
About 23andMe Holding Co.
23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 219.64M | 299.49M | 271.89M | 243.92M | 305.46M | 440.90M |
| Cost of Revenue | 120.26M | 164.99M | 138.95M | 126.91M | 168.03M | 257.91M |
| Gross Profit | 99.38M | 134.50M | 132.95M | 117.01M | 137.43M | 182.99M |
| Gross Profit Ratio | 45.25% | 44.91% | 48.90% | 47.97% | 44.99% | 41.50% |
| Research & Development | 205.36M | 222.60M | 189.38M | 159.86M | 181.28M | 140.53M |
| General & Administrative | 148.33M | 115.98M | 97.38M | 99.15M | 59.39M | 50.29M |
| Selling & Marketing | 85.60M | 119.93M | 100.34M | 43.20M | 110.52M | 190.85M |
| SG&A | 205.74M | 235.91M | 197.72M | 142.35M | 169.91M | 231.24M |
| Other Expenses | 9.63M | -93.00K | -83.00K | 1.32M | 1.34M | 0.00 |
| Operating Expenses | 420.73M | 458.51M | 387.10M | 302.20M | 351.19M | 371.77M |
| Cost & Expenses | 540.99M | 623.50M | 526.05M | 429.12M | 519.22M | 629.68M |
| Interest Income | 14.33M | 9.68M | 277.00K | 1.58M | 6.24M | 5.25M |
| Interest Expense | 0.00 | 0.00 | 277.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 29.48M | 36.50M | 26.15M | 20.25M | 22.25M | 9.90M |
| EBITDA | -291.87M | -291.94M | -228.01M | -164.95M | -191.51M | -173.63M |
| EBITDA Ratio | -132.89% | -96.00% | -95.99% | -67.62% | -47.72% | -40.57% |
| Operating Income | -321.36M | -324.01M | -254.15M | -185.20M | -213.76M | -188.78M |
| Operating Income Ratio | -146.31% | -108.19% | -93.48% | -75.92% | -69.98% | -42.82% |
| Total Other Income/Expenses | -345.28M | 9.58M | 33.18M | 1.58M | -37.11M | 5.25M |
| Income Before Tax | -666.63M | -314.43M | -220.97M | -183.62M | -250.86M | -183.53M |
| Income Before Tax Ratio | -303.51% | -104.99% | -81.27% | -75.28% | -82.13% | -41.63% |
| Income Tax Expense | 73.00K | -2.77M | -3.48M | -255.00K | 38.45M | 9.74M |
| Net Income | -666.70M | -311.66M | -217.49M | -183.36M | -289.31M | -183.53M |
| Net Income Ratio | -303.55% | -104.06% | -79.99% | -75.17% | -94.71% | -41.63% |
| EPS | -1.40 | -13.81 | -9.96 | -9.04 | -12.34 | -9.03 |
| EPS Diluted | -28.01 | -13.81 | -9.96 | -9.04 | -12.34 | -9.03 |
| Weighted Avg Shares Out | 475.98M | 22.58M | 21.83M | 20.32M | 20.32M | 20.32M |
| Weighted Avg Shares Out (Dil) | 23.80M | 22.58M | 21.83M | 20.32M | 20.32M | 20.32M |
23andMe sees independent board directors quit en masse
23andMe CEO Anne Wojcicki 'surprised and disappointed' by board resignations: Read the memo
23andMe independent directors quit board over unsatisfactory buyout plan from CEO
Independent Directors of 23andMe Resign from Board
23andMe Reportedly Paying $30 Million to Settle Data Breach Suit
23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study
23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial
23andMe settles data breach lawsuit for $30 million
One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations
23andMe CEO Wojcicki open to third-party takeover proposals for firm, filing shows
Source: https://incomestatements.info
Category: Stock Reports